Search Result

Results for "

good pharmacokinetic profile

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (2) Aminopeptidase (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (1) ATM/ATR (1) ATP Citrate Lyase (1) CDK (1) Cytochrome P450 (1) DNA/RNA Synthesis (1) ERK (1) Glycosidase (1) GSK-3 (1) HCV (3) HIV (1) Interleukin Related (1) JNK (1) Keap1-Nrf2 (1) Methylenetetrahydrofolate Dehydrogenase (MTHFD) (1) mTOR (1) Neprilysin (1) NF-κB (1) p38 MAPK (1) Parasite (1) Pim (1) Potassium Channel (1) Reverse Transcriptase (1) Sodium Channel (1) Topoisomerase (1) WDR5 (1)
By Research Areas:	Cancer (8) Cardiovascular Disease (3) Infection (3) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (3)

By Targets:

Adenosine Receptor (2)

Aminopeptidase (1)

Antibody-Drug Conjugates (ADCs) (1)

Apoptosis (1)

ATM/ATR (1)

ATP Citrate Lyase (1)

CDK (1)

Cytochrome P450 (1)

DNA/RNA Synthesis (1)

ERK (1)

Glycosidase (1)

GSK-3 (1)

HCV (3)

HIV (1)

Interleukin Related (1)

JNK (1)

Keap1-Nrf2 (1)

Methylenetetrahydrofolate Dehydrogenase (MTHFD) (1)

mTOR (1)

Neprilysin (1)

NF-κB (1)

p38 MAPK (1)

Parasite (1)

Pim (1)

Potassium Channel (1)

Reverse Transcriptase (1)

Sodium Channel (1)

Topoisomerase (1)

WDR5 (1)

By Research Areas:

Cancer (8)

Cardiovascular Disease (3)

Infection (3)

Inflammation/Immunology (3)

Metabolic Disease (2)

Neurological Disease (3)

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-130251

DS18561882 20+ Cited Publications	Methylenetetrahydrofolate Dehydrogenase (MTHFD)	Cancer
DS18561882 is a highly potent, isozyme-selective methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) inhibitor with an IC₅₀ value of 0.0063 μM. DS18561882 also has inhibitory effect on MTHFD1 (IC₅₀=0.57 μM). DS18561882 exhibits a good oral pharmacokinetic profile .

HY-164729

FZ-AD005	Antibody-Drug Conjugates (ADCs) Topoisomerase Apoptosis	Cancer
FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The K_d value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer .

HY-114237

GDC-0276	Sodium Channel	Neurological Disease
GDC-0276 is a potent, selective, reversible and orally active NaV1.7 inhibitor with an IC₅₀ value of 0.4 nM. GDC-0276 is well tolerated and exhibits a good pharmacokinetic profile. GDC-0276 has the potential for the treatment of pain and to address shortcomings of existing pain medications, such as addiction and off-target side effects .

HY-143889

Senexin C	CDK	Cancer
Senexin C is a selective and orally active CDK8/19 inhibitor. Senexin C shows a strong tumor-enrichment pharmacokinetic (PK) profile and tumor-pharmacodynamic (PD) marker responses. Senexin C inhibits the growth of MV4-11 leukemia cells with good tolerability .

HY-150654

WDR5-IN-5	WDR5	Cancer
WDR5-IN-5 is an orally active and selective inhibitor of WIN site of WD repeat domain 5 (WDR5). WDR5-IN-5 exhibits anti-proliferative activity towards cancer cells and good pharmacokinetics profile in mice. WDR5-IN-5 shows high affinity to WDR5 and the binding affinity K_i value <0.02 nM .

HY-112081

BAY-707	DNA/RNA Synthesis	Cancer
BAY-707, a chemical probe, is a substrate-competitive, highly potent and selective inhibitor of MTH1(NUDT1) with an IC₅₀ of 2.3 nM. BAY-707 has a good pharmacokinetic (PK) profile to other MTH1 compounds and is well-tolerated in mice, but shows a clear lack of in vitro or in vivo anticancer efficacy .

HY-10096

TCS2002	GSK-3	Neurological Disease
TCS2002 (Compound 9b) is a highly selective, orally bioavailable and potent GSK-3β inhibitor with the IC₅₀ of 35 nM. TCS2002 shows good pharmacokinetic profiles including favorable BBB penetration. TCS2002 can be used for the research of Alzheimer’s disease .

HY-172914

ACLY-IN-1	ATP Citrate Lyase	Cardiovascular Disease Metabolic Disease
ACLY-IN-1 is an orally active ACLY inhibitor. ACLY-IN-1 exhibits potent ACLY inhibitory activity (IC₅₀ = 8.3 nM) and high binding affinity (K_D = 72.0 nM) to ACLY. ACLY-IN-1 demonstrates good pharmacokinetic profiles and a potent in vivo hypolipidemic effect .

HY-123353

Neladenoson dalanate Neladenoson bialanate; BAY-1067197	Adenosine Receptor	Cardiovascular Disease
Neladenoson dalanate (Neladenoson bialanate; BAY-1067197) is a orally active agonist precursor of partial Adenosine A1 Receptor. Neladenoson dalanate has a good pharmacokinetic and safety profile, can be used for the chronic heart diseases .

HY-132867

MNK/PIM-IN-1	Pim	Cancer
MNK/PIM-IN-1 represents an innovative dual MNK/PIM inhibitor with a good pharmacokinetic profile.

HY-174417

NNRT-IN-10	Reverse Transcriptase HIV Potassium Channel Cytochrome P450	Infection
NNRT-IN-10 is a potent, selective and orally active non-nucleoside HIV-1 reverse transcriptase (NNRTI) inhibitor with with an EC₅₀ values ranging from 1.16 to 18.3 nM for HIV and its mutant strains. NNRT-IN-10 exhibits good pharmacokinetic properties and favorable safety profiles. NNRT-IN-10 can be used for the study of AIDS, caused by HIV-1 .

HY-133018

HCV-IN-7	HCV	Infection
HCV-IN-7 is an orally active and potent pan-genotypic HCV NS5A inhibitor with IC₅₀s of 3-47 pM. HCV-IN-7 shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. HCV-IN-7 has anti-viral activity .

HY-133018A

HCV-IN-7 hydrochloride	HCV	Cancer
HCV-IN-7 hydrochloride is an orally active and potent pan-genotypic HCV NS5A inhibitor with IC₅₀s of 3-47 pM. HCV-IN-7 hydrochloride shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. HCV-IN-7 hydrochloride has anti-viral activity .

HY-115494

Neladenoson dalanate hydrochloride Neladenoson bialanate hydrochloride; BAY-1067197 hydrochloride	Adenosine Receptor	Cardiovascular Disease
Neladenoson dalanate (Neladenoson bialanate; BAY-1067197) hydrochloride is a orally active agonist precursor of partial Adenosine A1 Receptor. Neladenoson dalanate hydrochloride has a good pharmacokinetic and safety profile, can be used for the chronic heart diseases .

HY-170797

α-Glucosidase-IN-80	Glycosidase	Metabolic Disease
α-Glucosidase-IN-80 (Compound 10n) is a potent competitive inhibitor of α-glucosidase, with an IC₅₀ of 48.4 μM. α-Glucosidase-IN-80 has good pharmacokinetic properties and toxicity profiles and can be used in the research of diabetes-related diseases .

HY-115989

HCV-IN-38	HCV	Infection
HCV-IN-38 is a potent, selective and orally active HCV inhibitor (EC₅₀=15 nM, SI=431). HCV-IN-38 has high anti-HCV activity and low cytotoxicity. HCV-IN-38 has a good safety and oral pharmacokinetic profile .

HY-151915

ATR-IN-20	ATM/ATR mTOR	Cancer
ATR-IN-20 is a potent ATR (ATM/ATR) inhibitor with an IC₅₀ of 3 nM. ATR-IN-20 possess an inhibitory effect on mTOR (IC₅₀ of 18 nM) while displaying good selectivity against PI3Kα (100 nM), ATM (100 nM), and DNA-PK (662 nM). ATR-IN-20 exhibits excellent pharmacokinetic profile (F = 30%), and has anticancer effects .

HY-170961

SDUY816	Aminopeptidase Neprilysin	Neurological Disease
SDUY816 is an oral active dual APN/NEP inhibitor, with IC₅₀ values of 0.68 μM for APN and 6.9 μM for NEP. SDUY816 exhibits analgesic effects and demonstrates good safety and pharmacokinetic profiles, with an oral bioavailability of 27% and a half-life of 4.02 hours in rats (oral administration, 10 mg/kg). SDUY816 has potential applications in the research of neuropathic pain disorders .

HY-125279

OAT-2068	Parasite	Inflammation/Immunology
OAT-2068 is a selective, high activity and orally active inhibitor of mouse chitotriosidase (mCHIT1) (IC₅₀=29 nM) and displays 143-fold selectivity over m AMCase (IC₅₀=4170 nM). OAT-2068 displays a good pharmacokinetic profile and is an ideal tool to study the role of CHIT1 in biological systems, including animal models of human diseases .

HY-157928

Keap1-Nrf2-IN-18	Keap1-Nrf2	Inflammation/Immunology
Keap1-Nrf2-IN-18 (Compound 22) is an orally active Keap1-Nrf2 protein-protein interaction (PPI) inhibitor with good pharmacokinetics (PK) profiles and more potent in vivo activities in rats. Keap1-Nrf2-IN-18 has the strongest inhibitory activity in structure−activity relationship (SAR) study (K_D = 0.0029 μM) .

HY-P11617

CLP-d2	NF-κB ERK JNK p38 MAPK Interleukin Related	Inflammation/Immunology
CLP-d2 is a multi-target anti-inflammatory agent, osteoclastogenesis inhibitor and immunomodulator with superior pharmacokinetic properties to Daptomycin (HY-B0108) and good safety profiles. CLP-d2 inhibits the NF-κB and MAPK signaling pathways by reducing the expression levels of c-Fos and NFATc1, and decreasing the phosphorylation levels of IκBα, p65, ERK and JNK, thereby reducing the secretion of pro-inflammatory cytokines such as IL-6, TNF-α and IL-1β to exert anti-inflammatory activity. CLP-d2 inhibits intra-articular osteoclastogenesis in mice, alleviates bone erosion and joint swelling, reduces synovial hyperplasia and inflammatory cell infiltration, and decreases serum rheumatoid factor (RF) levels. CLP-d2 is applicable to related research on rheumatoid arthritis .

Cat. No.	Product Name	Type

HY-164729

FZ-AD005	Fluorescent Dyes
FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The K_d value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer .

FZ-AD005

Fluorescent Dyes

FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The K_d value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer .

Cat. No.	Product Name	Target	Research Area

HY-P11617

CLP-d2	NF-κB ERK JNK p38 MAPK Interleukin Related	Inflammation/Immunology
CLP-d2 is a multi-target anti-inflammatory agent, osteoclastogenesis inhibitor and immunomodulator with superior pharmacokinetic properties to Daptomycin (HY-B0108) and good safety profiles. CLP-d2 inhibits the NF-κB and MAPK signaling pathways by reducing the expression levels of c-Fos and NFATc1, and decreasing the phosphorylation levels of IκBα, p65, ERK and JNK, thereby reducing the secretion of pro-inflammatory cytokines such as IL-6, TNF-α and IL-1β to exert anti-inflammatory activity. CLP-d2 inhibits intra-articular osteoclastogenesis in mice, alleviates bone erosion and joint swelling, reduces synovial hyperplasia and inflammatory cell infiltration, and decreases serum rheumatoid factor (RF) levels. CLP-d2 is applicable to related research on rheumatoid arthritis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.